Immunome Inc.
IMNMUnited States
24 filed reports · 313 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
24 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 1,997 | Sep 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 1,705 | Dec 2020 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 261 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 12, 2026 | 162 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 3, 2026 | 471 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 195 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 111 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 121 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 19, 2025 | 299 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 114 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 12, 2024 | 103 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 14, 2024 | 106 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 28, 2024 | 254 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 98 | Open |
Financial data
313 concepts · 3,702 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial304 concepts · 3,597 facts · Jun 2019 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value35 · Sep 2019 to Jun 2026
- Allocated share based compensation expense35 · Sep 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents35 · Sep 2019 to Jun 2026
- General and administrative expense (US GAAP)35 · Sep 2019 to Jun 2026
- Interest income expense net35 · Sep 2019 to Jun 2026
- Net income loss35 · Sep 2019 to Jun 2026
- Operating expenses (US GAAP)35 · Sep 2019 to Jun 2026
- Operating income loss35 · Sep 2019 to Jun 2026
- Research and development expense35 · Sep 2019 to Jun 2026
- Stockholders equity (US GAAP)35 · Sep 2019 to Jun 2026
- Accrued expenses and other current liabilities34 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2019 to Jun 2026
- Depreciation depletion and amortization34 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable34 · Dec 2019 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets34 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities34 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities34 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities34 · Dec 2019 to Jun 2026
- Payments to acquire property plant and equipment34 · Dec 2019 to Jun 2026
- Share based compensation34 · Dec 2019 to Jun 2026
- Cash and cash equivalents at carrying value33 · Dec 2019 to Jun 2026
- Defined contribution plan cost recognized33 · Dec 2019 to Jun 2026
- Employee related liabilities current33 · Sep 2019 to Jun 2026
- Restricted cash noncurrent33 · Dec 2019 to Jun 2026
Segment9 concepts · 105 facts · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)13 · Dec 2023 to Jun 2026
- Interest income expense net13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)13 · Dec 2023 to Jun 2026
- Operating income loss13 · Dec 2023 to Jun 2026
- Single reportable segment13 · Dec 2023 to Jun 2026
- Revenue11 · Dec 2023 to Dec 2025
- Other research and development expense9 · Dec 2023 to Sep 2025
- In-process research and development7 · Dec 2023 to Dec 2025
Segments
105 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 105 facts
- Single Reportable105 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.